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Abstract objective To investigate trends in all-cause adult mortality after the roll-out of an antiretroviral
therapy (ART) programme in rural Uganda.
methods Longitudinal population-based cohort study of approximately 20 000 residents in rural
Uganda. Mortality in adults aged 15–59 years was determined for the 5-year period (1999–2003)
before introduction of ART in January 2004 and for the 5-year period afterwards. Poisson regression
was used to estimate mortality rate ratios (RRs) for the period before ART, 1 year after ART intro-
duction (from January 2004 to January 2005) and more than 1 year after ART introduction. Trends in
mortality were analysed by HIV status, age and sex.
results Before ART became available, the mortality rate (deaths per 1000 person-years) was
4.0 (95% CI = 3.3–4.8) among HIV-negative individuals and 116.4 (95% CI = 101.9–133.0) among
HIV-positive individuals. During the period January 2004–end November 2009, 279 individuals ac-
cessed ART. In the year after ART was introduced, the mortality rate (deaths per 1000 person-years)
among HIV-negative individuals did not change significantly (adjusted RR = 0.95, 95% CI = 0.61–
1.47), but among HIV-positive individuals dropped by 25% to 87.4 (adjusted RR = 0.75, 95%
CI = 0.53–1.06). In the period 2005–2009, the mortality rate (deaths per 1000 person-years) among
HIV-positive individuals fell further to 39.9 (adjusted RR = 0.33, 95% CI = 0.26–0.43). The effect was
greatest among individuals aged 30–44 years, and trends were similar in men and women.
conclusion The substantially reduced mortality rate among HIV-positive individuals after ART
roll-out lends further support to the intensification of efforts to ensure universal access to ART.
keywords antiretroviral therapy, mortality, HIV+, Masaka, Uganda
Introduction
Antiretroviral therapy (ART) has reduced HIV-related
morbidity and mortality in both developed (Mocroft et al.
2003) and developing countries (Jahn et al. 2008). How-
ever, treatment coverage for HIV-infected patients must
be provided and maintained on a sufficient scale for
individual-level health improvements to be translated into
population-level reductions in mortality. The need is
particularly urgent in sub-Saharan Africa, which bears the
brunt of the global HIV epidemic with an estimated
1.3 million HIV-related deaths in 2009 (72% of global
HIV-related mortality) (UNAIDS 2010).
Since 2003, there has been a rapid scale up of ART for
HIV-infected individuals in poor countries (UNA-
IDS ⁄WHO 2009). One of the important measures of
successful large-scale ART programmes is the effect on
population-level mortality. Monitoring the effectiveness
of ART at population level helps governments make
informed decisions about investments in ART programmes
and aids in estimations of the numbers of people with HIV
infection who will need health care in future. Very few
studies from sub-Saharan Africa on the population-level
effect of ART on mortality have been published. Recent
studies in Malawi (Floyd et al. 2010) and South Africa
(Herbst et al. 2009) have demonstrated a reduction in
population mortality shortly after introduction of ART.
However, there have been no studies yet of the population-
level impact of ART stratified by individuals’ HIV status.
Population-based cohort studies provide data on HIV-
related mortality that are more representative of the
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general population than data from clinic-based studies,
which provide information only on the morbidity and
mortality of individuals who have accessed health care.
An open population-based cohort established in rural
Uganda in 1989 provided the opportunity to investigate the
effect of ART introduction in 2004 on adult mortality.
Methods
Setting
Uganda has been recovering since 1986 from previous civil,
political and economic turmoil. The population is
approximately 30 million, annual gross national income is
$300 per capita and mean life expectancy at birth is
50 years (UNICEF 2008). Uganda is one of the countries in
Africa where the HIV epidemic was first reported and
which was initially very severely affected by HIV ⁄AIDS.
Peak national HIV seroprevalence was 18% in 1992, with
a subsequent 70% decline through the 1990s until reaching
a plateau of about 6% at the end of that decade (Kirungi
et al. 2006; UNAIDS 2006).
A general population cohort was established in 1989 in
rural south-west Uganda for the purposes of HIV
surveillance and now comprises approximately 20 000
residents of 25 neighbouring villages in Masaka district,
not far from Lake Victoria. There are no tarmac roads,
and access may be difficult during the rains. The
community comprises mostly people belonging to the
Baganda tribe, with 15% of Rwandese origin. Religious
affiliation is mostly Christian, with a significant Muslim
minority (28%). Half the population is under 15 years of
age. The vast majority of dwellings are distributed
throughout the countryside rather than clustered in
villages, which represent administrative areas demarcated
on maps rather than population centres. Study partici-
pants are mostly subsistence farmers. The main income-
earning activities are growing bananas, coffee and beans,
and trading in produce and fish (Nakibinge et al. 2009).
HIV prevalence in the study area declined from 8.5% in
1990 to 6.2% in 2000 but thereafter rose to 7.7% in
2005 (Shafer et al. 2008).
Annual population-based cohort HIV survey
Full details of the cohort and annual HIV serosurvey have
been published elsewhere (Kengeya-Kayondo et al. 1996;
Mbulaiteye et al. 2002). In brief, an annual household
surveys have been conducted since 1989, with all study
village residents eligible for inclusion. Community sensi-
tisation activities precede each survey round, including
local council briefings and village meetings. All house-
holds are visited by teams, which undertake, in turn,
mapping, census (recording births, deaths and in- and
out-migrants) and survey. Consenting residents aged at
least 3 years are interviewed at home in the local
language by trained survey staff and provide a blood
sample for HIV testing. Survey participants who indicate
that they would like to receive their HIV test result are
referred to local voluntary counselling and testing (VCT)
centres, where they are informed of their result and
counselled.
ART programme in the study clinic
In January 2004, ART became available in the study clinic.
Eligibility is determined according to Uganda Ministry of
Health criteria: CD4 cell count of 200 cells ⁄ll (250 cells ⁄ll
if pregnant) or below, WHO clinical stage 4 disease or
advanced stage 3 disease with persistent or recurrent oral
thrush or invasive bacterial infections regardless of CD4
count (Ministry of Health, Republic of Uganda 2003).
Cotrimoxazole prophylaxis is given according to the
Ministry of Health guidelines (Ministry of Health,
Republic of Uganda 2005). Other HIV-positive individuals
from the population cohort who present at the study clinic
with symptoms and signs of HIV infection, and those
identified through attendance at the local VCT centres, are
also offered ART care if required and if they accept are also
enrolled in the clinical cohort.
By the end of 2008, overall ART coverage in the
programme was 69% (Kazooba et al. 2012). As the
research clinic is the only ART provider in the locality, it
is likely that only very few ART-eligible individuals from
the study population access ART from other providers.
Eligible patients are intensively prepared through three
counselling visits and a medical examination before start-
ing ART and thereafter are followed-up regularly at the
clinic. First-line treatment consists of a combination of
zidovudine (AZT), lamivudine (3TC) and nevirapine
(NVP), with a possibility of switching to stavudine (d4T) in
case of AZT toxicity and to efavirenz in case of NVP
toxicity or concurrent tuberculosis treatment.
Statistical methods
We assessed overall mortality rates in all adults aged 15–
59 years in the general population cohort over the 10-year
period from 1999 to 2009. We chose to focus on this age
range as it is mostly affected by HIV-related mortality.
Person-time was defined from the date the individual was
first seen in the census or was aged 15 years, whichever
was later, until the earliest of date of death, migration out
of the area, last seen in the census or age 60. Multiple
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episodes of observation and gaps were allowed, if indi-
viduals moved out of the surveillance area and later
returned. Gaps of <2 years were ignored.
Mortality rates were compared between three periods:
during the 5 years before the start of the national roll-out
in January 2004, during the 1 year after ART become
available in the area (from January 2004 until January
2005, denoted ART period 1) and during the 4-year
period from January 2005 until end 2009, denoted ART
period 2.
To assess mortality by HIV status, data were left-
truncated at the date of the first HIV test. Seroconverters
contributed deaths and person-years at risk to the HIV-
infected population from date of their first positive HIV
test. They also contributed person-years at risk to the
HIV-negative population before their last negative test.
Survival was evaluated using Kaplan–Meier curves. Pois-
son regression was used to estimate rate ratios (RR) for
mortality, stratified by age group and HIV status. Age-
stratified mortality RR were adjusted for sex to allow for
possible changes in the sex ratio over time.
Ethical considerations
The study received ethical approval from the Science and
Ethics Committee of the Uganda Virus Research Institute
and the Uganda National Council of Science and Tech-
nology. Use of unique identifying numbers ensured
participants’ confidentiality.
Results
Between 1999 and November 2009, we recorded 686
deaths in 18 077 individuals aged 15–59 years during
76 989 person-years of observation, with a crude death
rate of 8.9 deaths per 1000 person-years (95% CI 8.3–9.6;
Table 1). Among the 18 077 individuals, 1333 (7.4%)
were known to be HIV-positive, including 476 who
Table 1 Number of individuals, observed
deaths, person-years of follow-up and crude
death rates
Adults 15–59, 1999–2009 Male Female All
Total individuals 8414 9663 18 077
Seroconverters 199 277 476
Seroprevalent 279 578 857
Uninfected 6568 7515 14 083
HIV status
unknown (never tested)
1368 1293 2661
Person-years of observation
All adults* 36 723 40 266 76 989
HIV uninfected 29 158 32 070 61 228
HIV positive 1768 2678 4446
HIV status
unknown
(never tested)
3397 2385 5782
Deaths 328 358 686
Seroconverters 47 57 104
Seroprevalent 106 130 236
Uninfected 124 114 238
HIV status
unknown
(never tested)
51 57 108
Mortality rate ⁄ 1000
person-years (95% CI)
All adults 8.9 (8.0–10.0) 8.9 (8.0–9.9) 8.9 (8.3–9.6)
HIV uninfected 4.3 (3.6–5.1) 3.6 (3.0–4.3) 3.9 (3.4–4.4)
HIV positive 86.5 (73.8–101.4) 69.8 (60.5–80.6) 76.5 (68.8–85.1)
HIV status unknown
(never tested)
15.0 (11.4–19.8) 23.9 (18.4–31.0) 18.7 (15.5–22.6)
*Total person years calculated from the date first seen in census or aged 15 years,
whichever was later, until earliest of date of out-migration, last seen in the census or age 60.
Includes the period before the date of the first HIV test, among those tested.
Data left truncated at date of first HIV test (person-years between date first seen in census
and first HIV test are ignored).
Person years calculated as described in *, among individuals who never had an HIV test.
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seroconverted during the period of observation. Of the
65 674 person-years of observation in persons of known
HIV status, 4446 person-years (6.8%) were contributed by
HIV-positive individuals.
Figure 1 shows survival probability between the ages of
15–60 years for the entire population, by sex, in the
5 years before ART became available and in the 5-year
period after the introduction of ART in 2004. Before
2004, the probability of dying from any cause between
the ages of 15 and 60 years was 51% for men (95%
CI = 45–57) and 44% for women (95% CI = 39–49).
During 2004–2009, it reduced to 38% (95% CI = 33–
44) for men and 32% (95% CI = 28–37) for women.
Mortality was significantly lower in 2005–2009 (ART
period 2) than in the 5 years before ART introduction
(in men, age-adjusted RR = 0.60, 95% CI = 0.47–0.76;
in women, age-adjusted RR = 0.57, 95% CI = 0.44–
Table 2 All-cause mortality in adults aged 15–59 years, pre- and post-ART roll-out*
Adults 15–59, 1999–2009, entire population
Deaths ⁄ pyrs (rate ⁄ 1000 pyr) Unadjusted RR (95% CI) Adjusted RR (95% CI)
All individuals P < 0.001 P < 0.001
0–5 years pre ART 390 ⁄ 35 626 (10.9) 1 1
ART period 1 71 ⁄ 7713 (9.2) 0.84 (0.65–1.08) 0.82 (0.64–1.06)
ART period 2 225 ⁄ 33 650 (6.7) 0.61 (0.52–0.72) 0.58 (0.50–0.68)
Stratified by sex
Male P < 0.001 P < 0.001
0–5 years pre ART 185 ⁄ 17 145 (10.8) 1 1
ART period 1 34 ⁄ 3671 (9.3) 0.86 (0.60–1.24) 0.84 (0.58–1.20)
ART period 2 109 ⁄ 15 907 (6.9) 0.64 (0.50–0.80) 0.60 (0.47–0.76)
Female P < 0.001 P < 0.001
0–5 years pre ART 205 ⁄ 18 481 (11.1) 1 1
ART period 1 37 ⁄ 4042 (9.2) 0.83 (0.58–1.17) 0.81 (0.57–1.15)
ART period 2 116 ⁄ 17 743 (6.5) 0.59 (0.47–0.74) 0.57 (0.45–0.71)
Stratified by age
15–29 years P = 0.06 P = 0.06
0–5 years pre ART 109 ⁄ 20 447 (5.3) 1 1
ART period 1 21 ⁄ 4259 (4.9) 0.92 (0.58–1.48) 0.92 (0.58–1.47)
ART period 2 67 ⁄ 17 980 (3.7) 0.70 (0.52–0.95) 0.70 (0.51–0.94)
30–44 years P < 0.001 P < 0.001
0–5 years pre ART 192 ⁄ 9853 (19.5) 1 1
ART period 1 34 ⁄ 2268 (15.0) 0.77 (0.53–1.11) 0.77 (0.53–1.11)
ART period 2 84 ⁄ 10 046 (8.4) 0.43 (0.33–0.55) 0.43 (0.33–0.55)
45–59 years P = 0.29 P = 0.29
0–5 years pre ART 89 ⁄ 5327 (16.7) 1 1
ART period 1 16 ⁄ 1185 (13.5) 0.81 (0.47–1.38) 0.81 (0.47–1.38)
ART period 2 74 ⁄ 5624 (13.2) 0.79 (0.58–1.07) 0.79 (0.58–1.07)
ART, antiretroviral therapy; RRs, rate ratios.
*ART roll-out defined as 1 January 2004.
Adjusted for sex and age (RRs for all individuals), age (RRs stratified by sex), or sex (RRs stratified by age).
ART period 1 defined as the first year after ART roll-out (1 January 2004 to 1 January 2005). ART period 2 defined as the 4-year period
from 1 January 2004 to 31 December 2009).
§All estimates include participants whose HIV status was unknown (never tested).
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Figure 1 Kaplan–Meier survival function for the entire study
population in the 5 years before (1999–2003) and after (2004–
2009) antiretroviral therapy introduction, by sex.
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0.71; Table 2). Furthermore, there was a non-significant
reduction in mortality in the first year after ART became
available (ART period 1; in men, age-adjusted RR = 0.84,
95% CI = 0.58–1.20; in women, age-adjusted RR = 0.81,
95% CI = 0.57–1.15; Table 2). In contrast, among indi-
viduals aged 60 years and older, overall mortality did not
change (age- and sex-adjusted RR = 1.01, 95% CI = 0.76–
1.36 in ART period 1 compared with pre-ART and
RR = 1.00, 95% CI = 0.84–1.20 in ART period 2; data
not shown).
Among the 325 individuals of known HIV status who
died in the 5-year period before ART introduction, 216
(66.4%) were HIV infected. Mortality rates by HIV status
are shown in Figure 2 and Table 3. In the 5 years before
ART became available, mortality (deaths per 1000
person-years) was 4.0 (95% CI = 3.3–4.8) among HIV-
negative individuals and 116.4 (95% CI = 101.9–133.0)
among HIV-positive individuals. During this period, the
estimated population-attributable fraction (PAF) of HIV
in adults aged 15–59 years was 64%. In the year after
ART was introduced (ART period 1), the mortality rate
(deaths per 1000 person-years) among HIV-negative
individuals was not significantly different (adjusted
RR = 0.95, CI = 0.61–1.47) but had shrunk by 25% to
87.4 (adjusted RR = 0.75, CI = 0.53–1.06) among HIV-
positive adults. In the period 2005–2009 (ART period 2),
mortality among HIV-negative individuals did not change
significantly (adjusted RR = 0.93, CI = 0.71–1.21); how-
ever, among HIV-positive individuals, it fell further to
39.9 deaths per 1000 person-years (adjusted RR = 0.33,
CI = 0.26–0.43). During the 5-year period after ART
introduction (2004–2009), the estimated PAF of HIV had
dropped to 45%. Among HIV-negative individuals, there
was no evidence of a difference in mortality trends
between age groups or between men and women (test for
interaction P = 0.55 and P = 0.96, respectively). Among
HIV-positive individuals, in the year after ART intro-
duction, the reduction in mortality was greatest among
those aged 45–59 years; thereafter, the impact was
greatest among individuals aged 30–44 years (P = 0.14,
test for interaction). There was no evidence of a difference
in mortality trends between men and women (P = 0.76,
test for interaction).
There was a 27-fold increased mortality risk in HIV-
positive compared with HIV-negative individuals aged 15–
59 before ART introduction, which fell after ART intro-
duction to 21-fold in the first year (ART period 1; adjusted
RR = 21.5, 95% CI = 12.9–36.0) and ninefold in the
subsequent 4 years (ART period 2; adjusted RR 9.4, 95%
CI = 7.0–12.5) (Table 4). The trends of falling mortality
risk after ART introduction were similar in each age group
(Table 4).
Discussion
Our results show the considerable effect of HIV on
mortality at the population level and the substantial
reversal of this effect by introduction of ART. During
the 5-year period after ART introduction in 2004, over-
all mortality in adults decreased by 32% in men and 37%
in women. Although there was some reduction in overall
adult mortality in the first year after ART introduction,
the largest effect was seen in the subsequent 4 years. Our
findings indicate that, among adults aged 15–59 years,
the PAF of HIV in the 5 years before ART introduction
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was 64% and had fallen to 45% in the 5 years after
ART was introduced.
The non-significant reduction in mortality in the first
year after ART introduction may be the result of several
factors. When ART was first introduced, many of those
starting therapy may have entered the program with more
advanced disease and lower CD4 counts than the current
thresholds for ART initiation (CD4 < 250), and thus
mortality may have been higher. ART uptake in 2004 may
have been lower than in subsequent years, because fewer
people knew their HIV-positive status. From 2004 to 2006,
only 46% of HIV-positive persons knew their status, while
in 2008, 56% knew their status (Kazooba et al. 2012).
A recent study in South Africa found a significant drop in
standardised all-cause mortality in adults aged 25–49 years
in the 2 years after ART introduction: 16% in men and 8%
in women (Herbst et al. 2009). In a study in rural northern
Malawi in which ART scale-up started in 2005 and
reached 70% coverage in 2008, all-cause mortality rate
among 15–59 year olds fell by 32% (Floyd et al. 2010).
However, HIV prevalence in both cohorts (21.5% in South
Africa and 11.4% in Malawi) is higher than in our study
cohort. The reduction in mortality in Malawi was greater
in the area near the main roads and thus closer to the ART
clinic. Estimated ART coverage in our cohort in 2008, at
69% (Kazooba et al. 2012), is similar to that in the Malawi
study but lower than coverage in the South Africa study
area (estimated at 84% in 2006).
When separated by HIV status, we found no evidence of
change in mortality among the HIV-negative adults but a
significant reduction among HIV-positive adults. Thus, the
drop in mortality we observed at the population level is
Table 3 All-cause mortality in adults aged 15–59 years from 1999 to 2009, pre- and post-ART roll-out*, by HIV status
HIV negative HIV positive
Deaths ⁄ pyrs
(rate ⁄ 1000 pyr)
Adjusted RR
(95% CI)
Deaths ⁄ pyrs
(rate ⁄ 1000 pyr)
Adjusted RR
(95% CI)
All individuals
Time relative to ART roll-out P = 0.86 P < 0.001
0–5 years pre ART 109 ⁄ 27 402 (4.0) 1 216 ⁄ 1855 (116.4) 1
ART period 1 24 ⁄ 6306 (3.8) 0.95 (0.61–1.47) 38 ⁄ 435 (87.4) 0.75 (0.53–1.06)
ART period 2 105 ⁄ 27 519 (3.8) 0.93 (0.71–1.21) 86 ⁄ 2156 (39.9) 0.33 (0.26–0.43)
Stratified by sex
Male P = 0.82 P < 0.001
0–5 years pre ART 58 ⁄ 13 100 (4.4) 1 98 ⁄ 780 (125.6) 1
ART period 1 12 ⁄ 2992 (4.0) 0.89 (0.48–1.66) 16 ⁄ 174 (92.0) 0.73 (0.43–1.24)
ART period 2 54 ⁄ 13 066 (4.1) 0.89 (0.62–1.29) 39 ⁄ 814 (47.9) 0.36 (0.25–0.52)
Female P = 0.98 P < 0.001
0–5 years pre ART 51 ⁄ 14 302 (3.6) 1 118 ⁄ 1075 (109.8) 1
ART period 1 12 ⁄ 3315 (3.6) 1.01 (0.54–1.89) 22 ⁄ 261 (84.3) 0.77 (0.49–1.21)
ART period 2 51 ⁄ 14 453 (3.5) 0.97 (0.66–1.43) 47 ⁄ 1342 (35.0) 0.31 (0.22–0.43)
Stratified by age
15–29 years P = 0.99 P = 0.004
0–5 years pre ART 38 ⁄ 16 138 (2.4) 1 52 ⁄ 641 (81.1) 1
ART period 1 8 ⁄ 3601 (2.2) 0.94 (0.44–2.02) 10 ⁄ 141 (71.0) 0.88 (0.44–1.72)
ART period 2 36 ⁄ 15 237 (2.4) 1.00 (0.64–1.58) 21 ⁄ 578 (36.3) 0.45 (0.27–0.74)
30–44 years P = 0.27 P < 0.001
0–5 years pre ART 36 ⁄ 6994 (5.1) 1 121 ⁄ 964 (125.5) 1
ART period 1 5 ⁄ 1701 (2.9) 0.57 (0.22–1.46) 25 ⁄ 241 (103.8) 0.83 (0.54–1.28)
ART period 2 28 ⁄ 7641 (3.7) 0.71 (0.43–1.16) 39 ⁄ 1185 (32.9) 0.26 (0.18–0.38)
45–59 years P = 0.72 P < 0.001
0–5 years pre ART 35 ⁄ 4270 (8.2) 1 43 ⁄ 250 (171.9) 1
ART period 1 11 ⁄ 1004 (11.0) 1.34 (0.68–2.63) 3 ⁄ 53 (56.4) 0.33 (0.10–1.05)
ART period 2 41 ⁄ 4641 (8.8) 1.08 (0.69–1.69) 26 ⁄ 393 (66.1) 0.39 (0.24–0.63)
ART, antiretroviral therapy; RRs, rate ratios.
*ART roll-out defined as 1 January 2004.
Adjusted for sex and age (RRs for all individuals), age (RRs stratified by sex), or sex (RRs stratified by age).
ART period 1 defined as the first year after ART roll-out (1 January 2004 to 1 January 2005). ART period 2 defined as the 4-year period
from 1 January 2004 to 31 December 2009).
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explained by fewer deaths among HIV-positive persons.
From 2004 onwards, HIV-positive participants in the
clinical cohort received cotrimoxazole in addition to ART.
As cotrimoxazole reduces mortality (Mermin et al. 2004,
World Health Organization 2006a,b), the marked reduc-
tion in mortality among HIV-positive adults in our study
population may reflect the availability and uptake of both
cotrimoxazole and ART.
Using the previous WHO guidelines, in which the
CD4 cell count threshold for ART initiation was 200
cells ⁄mm3 (World Health Organization 2006a,b), esti-
mated national ART coverage in Uganda in 2007 was
33% (UNAIDS 2008). In our cohort, 48% of the HIV-
positive adults were estimated to need ART in 2008, and
overall estimated ART coverage, as a proportion of the
estimated number in need of treatment was 69%
(Kazooba et al. 2012). This is higher than the national
coverage but far from ideal. While in principle all ART-
eligible individuals had access to ART, not all of them
made use of the opportunity, partly because they did not
ask to be tested, partly because some did not want to be
enrolled on ART.
Our estimated mortality rates in this study differ from
the previous reports of mortality in this setting, based on
a clinical cohort drawn from the general population
cohort (Van der Paal et al. 2007). This is in part owing
to differences in the composition of the two groups, in
particular the older age distribution of HIV-negative
individuals in the clinical cohort.
A strength of this study is that the annual population
cohort survey collects demographic data, including infor-
mation on dates of birth, death and in- and out-migration,
allowing us precise denominators to calculate mortality
rates. Dates of HIV infection can also be estimated
reasonably well because of the annual serosurvey. A
limitation of the study is that average annual serosurvey
participation is about 60–65%, although a much higher
percentage has ever participated. For example, although
only 65% of residents aged 13 years and older participated
in the 2008–2009 serosurvey, 84% had ever participated in
a previous year. Based on the current mortality in
individuals who have never been tested for HIV (12.7 per
1000 person-years in 2005–2009), we estimate around
26% of those who have never participated to be HIV
positive.
Despite encouraging VCT for HIV among all persons in
the general population cohort and referral of people with
HIV infection to the study clinic, substantial mortality
remains among HIV-positive individuals. Although mor-
tality among HIV-positive adults has fallen significantly
since the introduction of ART, it remains much higher than
mortality among HIV-negative adults, particularly in theT
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younger age groups. Before HIV-related mortality falls
to levels seen in developed countries, a much larger
proportion of HIV-positive persons will need to find out
their HIV serostatus and be referred early to obtain care at
an earlier stage of HIV infection. In addition to benefits for
individuals, greater proportions of people who know their
HIV status early and of people with HIV infection who
start ART early may confer population-level benefits
through lowered viral loads, less infectivity and reduced
HIV transmission (Garnett & Baggaley 2009).
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